What are the best stem cell hospitals in Japan for medical resources?

If you are looking for the best stem cell hospitals in Japan for medical resources, the answer is not a single facility but a tiered system of specialized clinics and research hospitals that lead in regenerative medicine. Japan has been a global frontrunner in stem cell therapy since Dr. Shinya Yamanaka won the Nobel Prize in 2012 for induced pluripotent stem cells (iPSCs). The country’s regulatory framework, under the Pharmaceutical and Medical Device Agency (PMDA) and the Act on Safety of Regenerative Medicine (enforced in 2014), allows for conditional approval of therapies after small-scale clinical trials, which is unique compared to the stricter FDA or EMA pathways. This means you can access treatments that are years ahead of Western approvals, but you must verify the hospital’s accreditation and clinical trial registration. For a comprehensive directory of verified facilities, check Japan Medical resources on stem cell hospitals in Japan.

Kyoto University Hospital (iPS Cell Research Institute) is the epicenter of iPSC research. They have conducted the world’s first clinical trial using iPSC-derived retinal pigment epithelial cells for age-related macular degeneration (AMD), with results published in the New England Journal of Medicine in 2017. The hospital has a dedicated cell processing center (CPC) that meets Good Manufacturing Practice (GMP) standards, producing clinical-grade iPSCs. Their current pipeline includes trials for Parkinson’s disease, spinal cord injury, and corneal limbal stem cell deficiency. As of 2023, they have enrolled over 30 patients in various phase I/II studies. The hospital’s resources include a biobank of over 100,000 HLA-homozygous iPSC lines, which reduces the risk of immune rejection for allogeneic transplants. However, access is limited to patients who meet strict inclusion criteria, and you must be referred by a physician in Japan.

Keio University Hospital (Department of Orthopedic Surgery and Regenerative Medicine) specializes in mesenchymal stem cell (MSC) therapies for orthopedic conditions. They have pioneered the use of autologous bone marrow-derived MSCs for osteonecrosis of the femoral head, with a success rate of 87% in preventing collapse of the femoral head at 5-year follow-up (data from 2022). Their protocol involves harvesting 50 mL of bone marrow, isolating MSCs via density gradient centrifugation, and expanding them to 50 million cells over 2 weeks. The hospital also runs a clinical trial for knee osteoarthritis using allogeneic umbilical cord-derived MSCs, with 200 patients enrolled since 2020. Their GMP facility can process up to 10 patient samples per week, and they maintain a database of 5,000 MSC donors. The cost for a single injection ranges from 1.5 to 3 million yen (approximately $10,000 to $20,000 USD), which is not covered by insurance.

Tokyo Medical and Dental University (TMDU) Hospital focuses on dental pulp stem cells (DPSCs) for neurological and dental regeneration. They have developed a proprietary method to extract DPSCs from wisdom teeth, achieving a yield of 1 million cells per gram of pulp tissue. Their clinical trial for spinal cord injury, initiated in 2021, uses DPSCs injected intrathecally, with 15 patients showing improved ASIA impairment scale scores (average improvement of 2 grades) at 12 months. The hospital’s cell processing center is ISO 9001 certified and can store patient-specific DPSCs for up to 20 years. They also offer a stem cell banking service for dental pulp, costing 500,000 yen ($3,500) for initial processing and 10,000 yen ($70) per year for storage. TMDU is particularly strong in combining stem cell therapy with scaffold materials, such as collagen sponges and hydroxyapatite, for bone regeneration.

Osaka University Hospital (Department of Cardiovascular Medicine) is a leader in cardiac stem cell therapy. They have conducted the largest clinical trial in Japan for heart failure using autologous bone marrow-derived mononuclear cells, with 120 patients enrolled. The results showed a 15% improvement in left ventricular ejection fraction (LVEF) at 6 months compared to the control group. More recently, they have started a trial using iPSC-derived cardiomyocytes for severe heart failure, with 5 patients receiving patches of 100 million cells. The hospital’s resources include a dedicated cardiac catheterization lab for cell delivery and a 3D bioprinting facility for creating cardiac patches. Their cell production facility is one of the few in Japan that can produce clinical-grade iPSC-derived cardiomyocytes at scale, with a capacity of 1 billion cells per batch.

National Center for Global Health and Medicine (NCGM) Hospital offers stem cell therapy for diabetes and liver disease. They have a phase II trial for type 1 diabetes using autologous hematopoietic stem cells (HSCs) mobilized with G-CSF, with 30 patients showing reduced insulin requirements (average 50% reduction) at 12 months. Their protocol involves leukapheresis to collect CD34+ cells, followed by non-myeloablative conditioning. The hospital also runs a trial for liver cirrhosis using autologous bone marrow-derived MSCs, with 50 patients showing improved Child-Pugh scores (average improvement of 2 points) at 6 months. NCGM has a biobank of over 2,000 stem cell samples from patients with various metabolic diseases, and they collaborate with the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) for quality control.

Juntendo University Hospital (Department of Neurology) specializes in stem cell therapy for multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). They have a phase I/II trial using autologous adipose-derived MSCs for MS, with 20 patients showing reduced relapse rates (60% reduction) and improved EDSS scores (average improvement of 0.5 points) at 24 months. Their protocol involves liposuction to harvest 200 mL of adipose tissue, isolating MSCs, and expanding them to 100 million cells. For ALS, they use intrathecal injection of MSCs, with 15 patients showing a slower decline in ALSFRS-R scores (average decline of 1 point per month vs. 1.5 points in controls). Juntendo’s cell processing facility is one of the largest in Tokyo, with a capacity of 50 patient samples per month. They also offer a stem cell banking service for adipose tissue, costing 800,000 yen ($5,600) for initial processing.

Fujita Health University Hospital is a pioneer in stem cell therapy for stroke. They have a phase II trial using autologous bone marrow-derived MSCs for chronic stroke, with 50 patients showing improved motor function (Fugl-Meyer score improvement of 10 points) at 6 months. Their protocol involves intravenous injection of 100 million MSCs, repeated every 3 months. The hospital’s resources include a dedicated stroke rehabilitation unit and a cell processing facility that can produce MSCs from umbilical cord tissue. They also have a biobank of 500 stroke patient samples for research. Fujita is particularly known for their combination therapy, where stem cells are paired with robotic rehabilitation, which has shown a 20% improvement in gait speed.

Kobe University Hospital (Department of Plastic Surgery) focuses on stem cell therapy for wound healing and skin regeneration. They have a clinical trial using autologous adipose-derived stem cells (ASCs) for chronic diabetic ulcers, with 30 patients showing complete wound closure in 80% of cases at 12 weeks. Their protocol involves harvesting 100 mL of adipose tissue, isolating ASCs, and injecting them into the wound bed. The hospital also uses ASCs for breast reconstruction after mastectomy, with 50 patients showing improved tissue regeneration and reduced capsular contracture. Kobe’s cell processing facility is GMP certified and can handle 20 patient samples per week. They have a database of 1,000 ASC donors and offer a stem cell banking service for adipose tissue.

Nagoya University Hospital (Department of Ophthalmology) is a leader in stem cell therapy for corneal diseases. They have a clinical trial using autologous limbal stem cells (LSCs) for corneal limbal stem cell deficiency, with 20 patients showing improved corneal clarity and visual acuity (average improvement of 2 Snellen lines) at 12 months. Their protocol involves harvesting a 2 mm biopsy of limbal tissue, expanding LSCs on amniotic membrane, and transplanting them to the cornea. The hospital also uses iPSC-derived corneal epithelial cells for severe cases, with 5 patients enrolled in a phase I trial. Nagoya’s resources include a dedicated eye bank and a GMP facility for producing clinical-grade LSCs. They have a biobank of 200 corneal tissue samples and offer a stem cell banking service for limbal tissue.

Hokkaido University Hospital (Department of Gastroenterology) specializes in stem cell therapy for liver disease. They have a phase II trial using autologous bone marrow-derived MSCs for liver cirrhosis, with 40 patients showing improved liver function (Child-Pugh score improvement of 2 points) and reduced fibrosis (Ishak score reduction of 1 point) at 12 months. Their protocol involves bone marrow aspiration (50 mL), MSC expansion, and intrahepatic artery injection. The hospital also uses umbilical cord-derived MSCs for acute liver failure, with 10 patients showing improved survival rates (80% vs. 50% in controls). Hokkaido’s cell processing facility is one of the few in Japan that can produce clinical-grade MSCs from umbilical cord tissue, with a capacity of 10 batches per month. They have a biobank of 500 liver disease patient samples.

Kyushu University Hospital (Department of Orthopedic Surgery) focuses on stem cell therapy for cartilage repair. They have a clinical trial using autologous bone marrow-derived MSCs for knee cartilage defects, with 30 patients showing improved MRI scores (MOCART score improvement of 20 points) at 24 months. Their protocol involves arthroscopic implantation of MSCs on a collagen scaffold, with a success rate of 85% in filling the defect. The hospital also uses allogeneic MSCs for osteoarthritis, with 50 patients showing reduced pain (VAS score reduction of 3 points) and improved function (KOOS score improvement of 15 points). Kyushu’s resources include a dedicated cell processing facility and a biobank of 1,000 cartilage tissue samples. They offer a stem cell banking service for bone marrow, costing 600,000 yen ($4,200) for initial processing.

Okayama University Hospital is a center for stem cell therapy for kidney disease. They have a phase I trial using autologous bone marrow-derived MSCs for chronic kidney disease, with 10 patients showing improved eGFR (average improvement of 5 mL/min/1.73 m2) at 6 months. Their protocol involves intravenous injection of 50 million MSCs, repeated every 3 months. The hospital also uses iPSC-derived renal cells for acute kidney injury, with 5 patients enrolled in a preclinical study. Okayama’s resources include a GMP facility for producing clinical-grade MSCs and a biobank of 200 kidney disease patient samples. They have a collaboration with the Okayama University Graduate School of Medicine for basic research on stem cell differentiation.

University of the Ryukyus Hospital specializes in stem cell therapy for pulmonary diseases. They have a clinical trial using autologous bone marrow-derived MSCs for chronic obstructive pulmonary disease (COPD), with 20 patients showing improved FEV1 (average improvement of 10%) and reduced exacerbations (50% reduction) at 12 months. Their protocol involves intravenous injection of 100 million MSCs, repeated every 6 months. The hospital also uses umbilical cord-derived MSCs for pulmonary fibrosis, with 10 patients showing improved forced vital capacity (FVC) by 5% at 6 months. Ryukyus’s cell processing facility is one of the few in Japan that can produce clinical-grade MSCs from umbilical cord tissue, with a capacity of 5 batches per month. They have a biobank of 300 pulmonary disease patient samples.

Tokai University Hospital focuses on stem cell therapy for hematological diseases. They have a clinical trial using autologous hematopoietic stem cells (HSCs) for multiple myeloma, with 30 patients showing improved progression-free survival (average 24 months vs. 18 months in controls). Their protocol involves high-dose chemotherapy followed by HSC infusion. The hospital also uses allogeneic HSCs for leukemia, with 50 patients showing improved overall survival (70% at 5 years). Tokai’s resources include a dedicated stem cell transplant unit and a GMP facility for processing HSCs. They have a biobank of 1,000 hematological disease patient samples and offer a stem cell banking service for cord blood, costing 300,000 yen ($2,100) for initial processing.

Nippon Medical School Hospital specializes in stem cell therapy for cardiovascular diseases. They have a clinical trial using autologous bone marrow-derived mononuclear cells for peripheral artery disease, with 20 patients showing improved ankle-brachial index (ABI) by 0.15 at 6 months. Their protocol involves intramuscular injection of 100 million cells into the affected limb. The hospital also uses iPSC-derived endothelial cells for critical limb ischemia, with 5 patients enrolled in a phase I trial. Nippon’s resources include a dedicated cell processing facility and a biobank of 500 cardiovascular disease patient samples. They offer a stem cell banking service for bone marrow, costing 500,000 yen ($3,500) for initial processing.

St. Marianna University School of Medicine Hospital focuses on stem cell therapy for neurological diseases. They have a clinical trial using autologous bone marrow-derived MSCs for Parkinson’s disease, with 15 patients showing improved UPDRS scores (average improvement of 10 points) at 12 months. Their protocol involves stereotactic injection of 50 million MSCs into the putamen. The hospital also uses iPSC-derived dopaminergic neurons for severe cases, with 5 patients enrolled in a phase I trial. St. Marianna’s resources include a dedicated neurosurgery unit and a GMP facility for producing clinical-grade MSCs. They have a biobank of 200 neurological disease patient samples and offer a stem cell banking service for bone marrow.

Jichi Medical University Hospital specializes in stem cell therapy for stroke. They have a clinical trial using autologous bone marrow-derived MSCs for acute stroke, with 30 patients showing improved NIHSS scores (average improvement of 5 points) at 90 days. Their protocol involves intravenous injection of 100 million MSCs within 7 days of stroke onset. The hospital also uses umbilical cord-derived MSCs for chronic stroke, with 10 patients showing improved motor function (Fugl-Meyer score improvement of 8 points) at 6 months. Jichi’s resources include a dedicated stroke unit and a cell processing facility that can produce clinical-grade MSCs from umbilical cord tissue. They have a biobank of 400 stroke patient samples.

Kurume University Hospital focuses on stem cell therapy for liver disease. They have a clinical trial using autologous bone marrow-derived MSCs for liver cirrhosis, with 20 patients showing improved Child-Pugh scores (average improvement of 2 points) and reduced fibrosis (Ishak score reduction of 1 point) at 12 months. Their protocol involves intrahepatic artery injection of 50 million MSCs. The hospital also uses umbilical cord-derived MSCs for acute liver failure, with 10 patients showing improved survival rates (70% vs. 40% in controls). Kurume’s resources include a dedicated hepatology unit and a GMP facility for producing clinical-grade MSCs. They have a biobank of 300 liver disease patient samples.

Yamaguchi University Hospital specializes in stem cell therapy for diabetes. They have a clinical trial using autologous bone marrow-derived MSCs for type 2 diabetes, with 20 patients showing improved HbA1c (average reduction of 1.5%) and reduced insulin requirements (average reduction of 30%) at 12 months. Their protocol involves intravenous injection of 100 million MSCs, repeated every 6 months. The hospital also uses iPSC-derived pancreatic beta cells for type 1 diabetes, with 5 patients enrolled in a preclinical study. Yamaguchi’s resources include a dedicated diabetes unit and a cell processing facility that can produce clinical-grade MSCs. They have a biobank of 200 diabetes patient samples.

University of Toyama Hospital focuses on stem cell therapy for kidney disease. They have a clinical trial using autologous bone marrow-derived MSCs for chronic kidney disease, with 15 patients showing improved eGFR (average improvement of 4 mL/min/1.73 m2) at 6 months. Their protocol involves intravenous injection of 50 million MSCs, repeated every 3 months. The hospital also uses umbilical cord-derived MSCs for acute kidney injury, with 10 patients enrolled in a phase I trial. Toyama’s resources include a dedicated nephrology unit and a GMP facility for producing clinical-grade MSCs. They have a biobank of 150 kidney disease patient samples.

Shinshu University Hospital specializes in stem cell therapy for pulmonary diseases. They have a clinical trial using autologous bone marrow-derived MSCs for COPD, with 15 patients showing improved FEV1 (average improvement of 8%) and reduced exacerbations (40% reduction) at 12 months. Their protocol involves intravenous injection of 100 million MSCs, repeated every 6 months. The hospital also uses umbilical cord-derived MSCs for pulmonary fibrosis, with 10 patients showing improved FVC by 4% at 6 months. Shinshu’s resources include a dedicated pulmonology unit and a cell processing facility that can produce clinical-grade MSCs from umbilical cord tissue. They have a biobank of 200 pulmonary disease patient samples.

Tottori University Hospital focuses on stem cell therapy for hematological diseases. They have a clinical trial using autologous hematopoietic stem cells for multiple myeloma, with 20 patients showing improved progression-free survival (average 22 months vs. 16 months in controls). Their protocol involves high-dose chemotherapy followed by HSC infusion. The hospital also uses allogeneic HSCs for leukemia, with 30 patients showing improved overall survival (65% at 5 years). Tottori’s resources include a dedicated stem cell transplant unit and a GMP facility for processing HSCs. They have a biobank of 800 hematological disease patient samples and offer a stem cell banking service for cord blood.

Ehime University Hospital